Efient

RSS

prasugrel

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 21/11/2022

Authorisation details

Product details
Name
Efient
Agency product number
EMEA/H/C/000984
Active substance
prasugrel
International non-proprietary name (INN) or common name
prasugrel
Therapeutic area (MeSH)
  • Acute Coronary Syndrome
  • Angina, Unstable
  • Myocardial Infarction
Anatomical therapeutic chemical (ATC) code
B01AC22
Publication details
Marketing-authorisation holder
Substipharm
Revision
24
Date of issue of marketing authorisation valid throughout the European Union
24/02/2009
Contact address

24 rue Erlanger
75016
Paris
France

Product information

29/09/2022 Efient - EMEA/H/C/000984 - T/0035

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).

Assessment history

How useful was this page?

Add your rating
Average
1 rating